Your session is about to expire
← Back to Search
TST001 for Cancer
Study Summary
This trial is testing a new antibody against various types of cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer is advanced and has been confirmed by lab tests.I have untreated advanced pancreatic cancer, but may have had prior therapy if my cancer returned 6 months after treatment ended.I have never been treated with CLDN18.2 targeting drugs.I haven't had another cancer within the last 5 years, except for certain treated types.I am 18 years old or older.My heart, liver, and kidneys are functioning well.I have symptoms from cancer spread to my brain.My stomach cancer worsened after 1 or 2 treatments.I have untreated advanced stomach cancer that has worsened 6 months after initial therapy.I am fully active or can carry out light work.I do not have any active, serious infections or uncontrolled hepatitis B or C, or HIV/AIDS.My cancer has not responded to standard treatments, or there are no standard treatments for it.My stomach cancer worsened after 1 or 2 treatments.I do not have severe heart issues or recent serious heart events.My cancer is advanced and has spread to other parts of my body.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
- Group 1: Part B Cohort A
- Group 2: Part B Cohort B
- Group 3: Part B Cohort C
- Group 4: Part A Q3W
- Group 5: Part A Q2W
Frequently Asked Questions
What is the cap on enrollment for this research project?
"To participate in this research, 124 suitable candidates must be found. The trial is occuring at multiple sites such as Yale University of New Haven, Connecticut and Sarah Cannon Research Institute located in Nashville, Tennessee."
What is the geographic scope of oversight for this experiment?
"Currently, 9 clinical trial sites are running this medical trial. They can be found in New Haven, Nashville and Canton to name a few. To reduce the burden of travel for participants, it is recommended that they find the closest site possible."
Is this clinical research recruitment open at the present?
"Clinicaltrials.gov currently lists this clinical trial as actively recruiting for participants, with its initial post date being May 28th 2020 and the most recent edit occurring on October 21st 2022."
What safety assessments have been conducted on TST001?
"The safety of TST001 is rated at 1 due to only preliminary data being available that suggests its efficacy and safety."
What are the fundamental goals of this trial?
"Bristol-Myers Squibb, the trial sponsor, has reported that Participant Safety and Tolerability of TST001 when combined with Nivolumab will be the primary outcome to measure over a 100 day interval after last dose. Secondary outcomes being assessed include Plasma Concentration vs Time Curve (AUC) changes for participants taking TST001, Maximum Serum Concentration (Cmax), and Duration of Response (DOR)."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger